TABLE 1.
Comparison of test results with FMDV NSP antibody evaluation panele
| Animal group | No. of animals seropositive/total no. of animals tested (%) |
||||
|---|---|---|---|---|---|
| 3B cELISA | PrioCheck NSa | Bommedib | UBIc | Svanovad | |
| Vaccinated carrier | 18/20 | 18/20 | 14/20 | 11/20 | 10/20 |
| Vaccinated noncarrier | 4/4 | 3/4 | 3/4 | 2/4 | 2/4 |
| Control carrier | 7/7 | 7/7 | 7/7 | 6/7 | 6/7 |
| Control noncarrier | 5/5 | 5/5 | 5/5 | 5/5 | 4/5 |
| Total | 34/36 (94) | 33/36 (92) | 29/36 (81) | 24/36 (67) | 22/36 (61) |
a
PrioCheck NS, Cedi Diagnostics B.V., Lelystad, The Netherlands.
b
Bommedi, Chekit-FMD-3ABC bo-ov, Bommeli Diagnostics, Liebefeld-Bern, Switzerland.
c
UBI, UBI FMDV NS ELISA (cattle), United Biomedical Inc., Hauppauge, NY.
d
Svanova, Svanovir FMDV 3ABC-Ab ELISA, Svanova Biotech AB, Uppsala, Sweden.
e
All animals (n = 36 animals from the vaccinated and control groups) were challenged and shown to be seropositive by VNT. The results of all tests except the 3B cELISA have previously been reported by Parida et al. (23).